Furthermore, the researchers extracted ≥1 PD-L1+ CTCs in 8% of patients with advanced stage III and IV NSCLC (n = 6/71 samples) with 93% concordance to PD-L1+ tumor cells of matched primary tissue (specificity = 100%; sensitivity = 55%). This evidence concerns the gene CD274 and non-small cell lung carcinoma.